Tim Witney is Chief Scientific Officer at Nuclide Therapeutics and Professor of Molecular Imaging at King’s College London. Over the past decade, his research, supported by more than £15 million in grant funding, has advanced next-generation molecular diagnostics to monitor treatment response and uncover mechanisms of therapeutic resistance in cancer.
A central focus of his work is the development of targeted radionuclide therapies that exploit the biological drivers of refractory disease. He holds seven patents in cancer theranostics and has led the clinical translation of multiple imaging agents, including two that have been commercially licensed.
Professor Witney is President of the European Society for Molecular Imaging and Editor-in-Chief of npj Imaging. He was named Cancer Research Horizon’s ‘Entrepreneurial Group Leader of the Year’ in 2025.
He obtained his PhD in Biochemistry from the University of Cambridge in 2010, where he trained under Professor Kevin Brindle FRS and contributed to establishing dynamic nuclear polarisation as a novel approach for assessing tumour response to therapy.
He subsequently joined Professor Eric Aboagye’s group at Imperial College London, where he developed innovative positron emission tomography radiotracers for cancer imaging, before undertaking further training at Stanford University with Professor Sanjiv Sam Gambhir, a pioneer in molecular imaging.
In 2015, Professor Witney established his independent research group at the Centre for Advanced Biomedical Imaging, University College London, supported by a UCL Excellence Fellowship and a Wellcome Trust–Royal Society Sir Henry Dale Fellowship, followed by a Wellcome Trust Senior Research Fellowship.
He moved to King’s College London in 2018 to take up his current appointment and was promoted to Professor at the age of 40.
